Categories
Remus Pharmaceuticals Limited — Board Meeting, 20-05-2026: Outcome of Board Meeting
20-05-2026 · 03:18 pm
Remus Pharma reports strong FY26 consolidated results: Revenue at ₹853.63 Cr (up 37.6%), PAT at ₹46.17 Cr (up 20.18%). The board declared a final dividend of ₹0.50 per share for FY26.
No comments yet. Be the first to comment!